Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing beneficial ownership of 396,718 shares of Imunon, Inc. common stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power via an Investment Management Agreement.
Imunon, Inc. reported a Q1 2026 net loss of $4.25M, slightly wider than the prior-year loss of $4.10M, as operating expenses rose to $4.31M driven mainly by higher research and development spending.
Cash and cash equivalents declined to $4.79M at March 31, 2026 from $8.78M at year-end, with $3.99M used in operating activities in the quarter. Management concludes there is substantial doubt about Imunon’s ability to continue as a going concern without new capital.
The company remains a clinical-stage biotech focused on its DNA-based immunotherapy IMNN-001 for advanced ovarian cancer. Final Phase 2 OVATION 2 data showed a 14.7‑month improvement in median overall survival versus standard chemotherapy alone, and a 24.2‑month gain in patients also receiving PARP inhibitors, supporting advancement into a Phase 3 pivotal trial.
IMUNON, Inc. reported a first quarter 2026 net loss of $4.3 million, or $0.84 per share, compared with a net loss of $4.1 million, or $3.15 per share, a year earlier. Operating expenses rose slightly to $4.3 million, driven mainly by research and development spending of $2.3 million as the company advances its OVATION 3 Phase 3 trial in advanced ovarian cancer. General and administrative costs were stable at $2.0 million.
Net cash used in operations was $4.0 million, and cash and cash equivalents totaled $4.8 million as of March 31, 2026. IMUNON highlighted final Phase 2 OVATION 2 data showing a 14.7‑month median overall survival increase with IMNN‑001 versus standard chemotherapy, and a 24.2‑month median overall survival increase when combined with standard chemotherapy and PARP inhibitors. The FDA has reviewed and is aligned with the Phase 3 protocol for IMNN‑001, confirming a path to a future BLA filing.
Imunon, Inc. entered into change of control agreements with its Chief Executive Officer and President Stacy Lindborg, Chief Medical Officer Douglas Faller, and General Counsel and Corporate Secretary Susan Eylward. These agreements define severance benefits if employment ends in connection with a corporate change in control.
If terminated without cause or leaving for good reason on or within one year after or four months before a change in control, Dr. Lindborg receives a lump sum of 2.5 times her annual base salary plus target bonus, while Dr. Faller and Ms. Eylward receive 1.5 times that sum. Imunon will also cover COBRA health and life insurance premiums for up to eighteen months for the two officers and twenty-four months for Dr. Lindborg, and fully accelerate their outstanding equity awards, subject to a release of claims.
Imunon, Inc. has issued its 2026 proxy statement for a fully virtual annual meeting on June 16, 2026. Stockholders will vote on electing two Class I directors through 2029, ratifying WithumSmith+Brown PC as auditor for 2026, and holding a non-binding advisory vote on 2025 executive pay.
They will also vote on amending the 2018 Stock Incentive Plan to increase the shares available for equity awards. The record date is April 17, 2026, with 3,983,342 common shares outstanding. The proxy outlines board structure, governance practices, ownership, and detailed 2025 compensation for key executives.
Imunon, Inc. files its Annual Report describing a clinical-stage pipeline and significant financial strain. The company ended December 31, 2025 with $8.8 million in cash and cash equivalents and recorded substantial doubt about its ability to continue as a going concern without new financing.
Lead ovarian cancer candidate IMNN-001 showed encouraging Phase 2 OVATION 2 results, including a final median overall survival increase of 14.7 months versus standard chemotherapy, and even larger gains when combined with PARP inhibitors. Imunon is enrolling a Phase 3 OVATION 3 trial after a favorable End-of-Phase II meeting with the FDA.
The company’s PlaCCine DNA vaccine platform also advanced, with COVID-19 booster candidate IMNN-101 demonstrating multi-fold, durable neutralizing antibody increases and good tolerability in a 24-subject Phase 1 study, though further development is currently paused while Imunon seeks partners and additional capital.
IMUNON, Inc. reported 2025 results and highlighted major advances in its ovarian cancer program. Final Phase 2 OVATION 2 data showed IMNN‑001 plus standard chemotherapy improved median overall survival to 45.1 months versus 30.4 months, and to 65.6 months versus 41.4 months when combined with PARP inhibitor maintenance, improvements the company describes as clinically meaningful.
Enrollment in the pivotal Phase 3 OVATION 3 trial remains ahead of plan. For 2025, IMUNON recorded a net loss of $14.5 million (vs. $18.6 million in 2024) as operating expenses fell 23% to $14.7 million, driven by lower R&D spending as earlier trials wound down. Year-end cash and cash equivalents were $8.8 million, supported by $17.1 million of 2025 financing, including a $7.0 million registered direct offering.
Imunon, Inc. filed a prospectus supplement to register an additional $7,000,000 of common stock under its at-the-market offering program with H.C. Wainwright & Co.
This increases the aggregate amount covered by the program to $17,000,000 of shares. Before this update, the company had already sold $4,797,848 of common stock through the sales agent under the existing agreement.
Imunon, Inc. amends its ATM prospectus supplement to increase the aggregate amount available for sale under its At the Market Offering Agreement with H.C. Wainwright & Co. to $17,000,000, adding $7,000,000 to the prior $10,000,000 authorization.
The sales program permits the company to offer and sell Common Stock from time to time pursuant to the Sales Agreement dated May 25, 2022, as amended. Through the date of this supplement the company has sold $4,797,848 under the program.